Sanofi, GSK Covid-19 Vaccine Program Is Delayed
December 11 2020 - 1:55AM
Dow Jones News
By Cecilia Butini
Sanofi SA said Friday that the Covid-19 vaccine program it is
developing with British pharmaceutical giant GlaxoSmithKline PLC
has experienced a delay.
The French pharmaceutical major said the program was to improve
immune response in the elderly, but Phase 1-2 interim results
showed insufficient immune response in that group.
Sanofi said the reason for the low immune response was probably
an insufficient concentration of the antigen utilized, and that the
two companies are planning a new study with an improved antigen
formulation to start in February 2021.
The vaccine is now expected to become available in the fourth
quarter of 2021, pending completion of the development plan.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
December 11, 2020 01:40 ET (06:40 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024
